Efficacy and safety were consistent across baseline cardiac index subgroups in PULSAR and STELLAR clinical trials, supporting use of sotatercept in PAH patients irrespective of baseline cardiac hemodynamics.
🔗: https://t.co/1tOYSsmnWV
Sacubitril/Valsartan in patients with HF & deterioration in eGFR to <30 with therapy. Continuation of ARNi was associated with persistent clinical benefit and no incremental risk. @JACCJournals#JACCHF https://t.co/m5BvBm0B4m
Molly Silkowski, DO (@MollySilkowski), and Anbukarasi Maran, MD (@ArasiMaran), provide an up-to-date assessment of coronary perforation, including a look at balloon tamponade, thrombin, and multiple technological management tools. https://t.co/buAW6D2xid
Drs. Harshith Chandrakumar (@harshithpriyan), Molly Silkowski (@MollySilkowski), & Anbukarasi Maran (@ArasiMaran), discuss calcific coronary lesion imaging & treatment, diving into the pros & cons of available imaging modalities & modification therapies.
https://t.co/HlxanQBi9Z
Had the best time meeting the leading figures in the world of cardiogenic shock and learning more about mechanics and the future of RV/LV unloading. Til next time ACURE!
SO honored and thrilled to continue my training at MUSC!
To be the best, you have to surround yourself with the best.
Cheers to spending a year with faculty that are incredibly talented and create the most comfortable learning environment. #wedgesat4all
In 2016, I watched my first coronary angiogram. @DrQuinnCapers4 took me to the cath lab after my @OhioStateMed interview.
7 years and innumerable guidance and mentorship sessions later I'm joining him as interventional cardiology faculty at @UTSWNews
Representation matters!